FF 10502

Drug Profile

FF 10502

Alternative Names: FF-10502-01

Latest Information Update: 26 Feb 2016

Price : $50

At a glance

  • Originator FUJIFILM Holdings Corporation
  • Developer Strategia Therapeutics
  • Class Antineoplastics
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Lymphoma; Solid tumours

Most Recent Events

  • 19 Feb 2016 Phase-I/II clinical trials in Solid tumours (Late-stage disease) and Lymphoma (Late-stage disease) in USA (IV) (NCT02661542)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top